Patents by Inventor Lars Herfurth

Lars Herfurth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS
    Publication number: 20130281429
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS
    Publication number: 20110251174
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • Pyrimidines as PLK inhibitors
    Publication number: 20110086842
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
  • Pyrimidines as PLK inhibitors
    Publication number: 20090163465
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: February 5, 2009
    Publication date: June 25, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
  • Pyrimidines as PLK inhibitors
    Publication number: 20090149438
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: February 5, 2009
    Publication date: June 11, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
  • Pyrimidines as PLK inhibitors
    Patent number: 7521457
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: April 21, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Harald Engelhardt, Martin Steegmaier, Anke Baum, Ulrich Guertler, Andreas Schoop, Jens Juergen Quant, Flavio Solca, Rudolf Hauptmann, Ulrich Reiser, Stephan Karl Zahn, Lars Herfurth
  • 2,4-diamino-pyrimidines as aurora inhibitors
    Publication number: 20070032514
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 8, 2007
    Inventors: Stephan Zahn, Guido Boehmelt, Andreas Mantoulidis, Ulrich Reiser, Matthias Treu, Ulrich Guertler, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Ralph Brueckner, Charlotte Reither, Lars Herfurth, Oliver Kraemer, Heinz Stadtmueller, Harald Engelhardt
  • Alpha-Carbolines as CDK-1 inhibitors
    Publication number: 20070004684
    Abstract: The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 8, 2006
    Publication date: January 4, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Sennhenn, Andreas Mantoulidis, Matthias Treu, Ulrike Tontsch-Grunt, Walter Spevak, Darryl McConnell, Andreas Schoop, Ralph Brueckner, Albrecht Jacobi, Ulrich Guertler, Gisela Schnapp, Christian Klein, Frank Himmelsbach, Alexander Pautsch, Bodo Betzmeier, Lars Herfurth, Juergen Mack, Dieter Wiedenmayer, Gerd Bader, Ulrich Reiser
  • Pyrimidines as PLK inhibitors
    Publication number: 20060148800
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: August 17, 2005
    Publication date: July 6, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Harald Engelhardt, Martin Steegmaier, Anke Baum, Ulrich Guertler, Andreas Schoop, Jen Quant, Flavio Solca, Rudolf Hauptmann, Ulrich Reiser, Stephan Zahn, Lars Herfurth